Avsnitt
-
As 2024 comes to a close, it's time to look back on a year in the pharmaceutical industry. In this final episode of the year, Isabel and Jade are joined by three former guest to reflect on the pivotal moments that defined the past 12 months.
They are joined by Jennifer Schranz from Ipsen, Martina Dempsey from Astellas and Elias Revonta, CEO of Orcason, who all return to the podcast to share their insights. Together, they’ll discuss the major trends, challenges and breakthroughs that shaped 2024, including advancements in oncology, gene therapy, rare diseases and the growing role of AI.
A little more on EMJ GOLD's guests...
Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen’s vision of addressing challenging rare diseases.
Martina Dempsey is the Vice President of Commercial Strategy & Operations at Astellas Europe, having worked with the business since 2014 in her home country of Ireland. In addition to her role at the pharma company, she also acts as a Board Member for the Irish Pharmaceutical Healthcare Association. Prior to her time at Astellas, she spent 13 years at GSK in various roles including in the regulatory affairs and business transformation sectors.
Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics.
-
In this final episode of the season, Isabel discusses how to normalise the conversation, not the suffering, around menopause with Dr Cecilia Caetano, Vice President, Head, Global Medical Affairs, Women’s Health, Bayer.
Menopause affects over 50% of the world’s population, but its symptoms and effects are often misunderstood or ignored. Find out how industry can help by equipping not only HCPs but also women with the knowledge and awareness to manage menopause on an individual level, debunking the myths and prejudices surrounding the topic and much more.
-
Saknas det avsnitt?
-
Season 8 is almost over, but before we release our finale episode, why not take a listen to some of our favourite moments from the last couple of months?
From an insight into why Gen Z might be turning their sails towards the pharmaceutical industry, to a call for a better understanding of HIV stigma, there’s plenty to discover in this season’s GOLD Medal Moments.
-
In this episode of the EMJ GOLD podcast, Jade and Isabel explore one of the most urgent global health issues: antimicrobial resistance (AMR). As part of World AMR Awareness Week, they are highlighting this year’s theme ‘Educate. Advocate. Act now’.
Joining the conversation is Elias Revonta, Founder and CEO, Orcason Medical, who shares his vision for tackling AMR through groundbreaking medical technology. Orcason Medical is pioneering point-of-care devices for ear, nose and throat conditions to address the overprescription of antibiotics—a vital measure in the fight against AMR.
A little more on GOLD’s guest…
Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development.
He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics. With a mission to combat the rise of AMR, his goal is to protect the power of antibiotics and improve the lives of millions of patients by enabling smarter, safer healthcare solutions. -
In this episode, Isabel welcomes Patrick Oliver, General Manager for the UK and Ireland at Alfasigma, to explore the company’s exciting entry into the UK market and the evolving landscape of healthcare in the country.
In the conversation, Patrick brings his wealth of industry experience to share his vision for Alfasigma’s future, the potential he sees in the UK healthcare market and the unique challenges ahead. They also delve into Lord Darzi’s report on the NHS, examining its implications for healthcare reform and innovation.
A little more on GOLD’s guest…
Patrick Oliver is Alfasigma’s General Manager for the UK & Ireland, a role he’s held since the company’s launch in the UK in early 2024. He has 36 years’ experience in the industry, with 16 years specifically in market access. Prior to joining Alfasigma, Patrick worked in market access for a number of large pharmaceutical companies including Johnson & Johnson, AbbVie and Abbott.
-
As 2024 draws to a close, what should pharma teams be focusing their budgets on for the final quarter of the year?
Join Jade and Isabel as they explore the critical trends that have shaped the industry in 2024. As teams finalise their budgets and plan for the final quarter and year ahead, this conversation brings insights into how strategies like personalised engagement, thought leadership and interactive, on-demand content are making an impact. With real-life examples, learn about the tools you can invest in to end the year on a high.
-
In this new episode, the team welcomes Jennifer Schranz, Senior Vice President, Global Head of Rare Diseases, Ipsen, to investigate the burden faced by women with rare diseases.
Together, Jennifer and Jade discuss how the industry can address challenging rare diseases and making a meaningful impact on patients’ lives, the double jeopardy that women with rare diseases face, recent breakthroughs in the space and much more.
-
In the latest episode of our podcast, we welcome Richard Lowenthal, CEO, ARS Pharmaceuticals, to explore the company’s mission to address unmet needs in allergy care.
During the conversation, Richard shares insights into his early career at the FDA and the regulatory challenges he faced in bringing ARS’s new nasal spray to treat severe allergic reactions to market. He also discusses the future direction of the company and much more.
A little more on EMJ GOLD’s guest…Richard Lowenthal is the co-founder, President, and CEO, ARS Pharmaceuticals, with a leadership role since the company’s inception in 2015. Before ARS, he founded Pacific-Link Regulatory Consulting, where he contributed to the development of their diazepam nasal spray. Richard’s extensive background includes senior roles at Cadence Pharmaceuticals, Maxim Pharmaceuticals and Janssen Research Foundation, as well as work as a chemist at the FDA. He holds an M.Sc. in organic chemistry and an MSEL and has chaired the American Association of Pharmaceutical Scientists.
-
In the latest episode, Jade sits down with Martina Dempsey, Vice President of Commercial Strategy and Operations at Astellas Europe, to discuss empowering women in the pharmaceutical industry.
They explore how pharma meets the needs and values of young graduates, the ongoing challenges women face in securing leadership roles, the critical impact of mentorship on career development and much more.
-
In this episode, Isabel is joined by Nedim Pipic, Senior Vice President and Global Therapeutic Area Head for Mental Health, Boehringer Ingelheim, to mark World Mental Health Day on 10 October 2024.
Their conversation dives into the unique challenges faced by those living with serious mental illnesses, the impact of media representation and the role pharma can play in transforming treatment and quality of life for these patients.
Central to their discussion is the importance of amplifying lived experiences, a key focus of Boehringer’s new campaign, Schizophrenia in Real Life: Stories of Challenges, Resilience, and Hope. The campaign aims to build greater understanding and acceptance of the condition by highlighting the strength and resilience of those living with it.
-
This week, Jean-Bernard Simeon, Senior Vice President and Head, ViiV Healthcare Europe, sits down with the EMJ GOLD team to share his thoughts on the current landscape for patients with HIV in Europe.
Together, JB and Jade explore the UNAIDS roadmap to end the HIV epidemic by 2030, the barriers faced by people living with HIV in Europe, stigmas still surrounding the condition and much more.
-
The EMJ GOLD podcast is back! In the first episode of season 8, Jade sits down with Chantal Friebertshäuser, Senior Vice President and General Manager, EMEAC, Moderna, to discuss how Europe can combat the recent erosion of trust in vaccines.
Together, the two explore the role of governments in addressing vaccine hesitancy, improving vaccine education amongst various groups, how a culture of collaboration can improve the current vaccine landscape and much more.
-
The new season of the podcast is only a week away, so before we get started – why not have a listen to some of the best bits from Series 7? From a deep dive into women’s health to why the industry thrives on a little healthy competition, there’s plenty to discover in last season’s highlights.
As well as the EMJ GOLD team’s analysis of the key themes, you’ll hear from six former guests:
Mercedes Diz, Chief Marketing Office, Almirall Nichole Davies, Global Chief Strategy Officer, VML Health Edmond Chan, Senior Director, EMEA TA Lead, Haemato-Oncology, J&J Stefan Woxström, Senior Vice President, Europe and Canada, AstraZeneca Danie Du Plessis, EVP, Pharmaceutical Operations, Kyowa Kirin Harmony Garges, Chief Medical Officer ViiV Healthcare. -
In this season finale of the EMJ GOLD podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma, about how he strives to challenge the status quo in the pharmaceutical industry.
The two discuss how Tadaaki’s time as a surgical oncologist has influenced his leadership style, how collaboration is key for making impacts for patients, the next game changers in cancer treatment and more.
A little bit more on EMJ GOLD’s guest…Dr Tadaaki Taniguchi leads Astellas’ global team in identifying, discovering and developing new treatments that have the potential to transform healthcare, with a focus on innovative and patient-centred therapies.
He has more than 20 years of industry experience spanning research, development and medical affairs, and has worked in a range of therapeutic areas including diabetes and oncology. Prior to joining Astellas, Tadaaki held senior positions at other major pharmaceutical companies in the US, Japan and China. Before joining the industry, he spent 10 years as a surgical oncologist – giving him a unique perspective on how to deliver breakthrough science that changes the way diseases are treated.
-
In this penultimate episode of Season 7, Isabel and Jade sit down to discuss EMJ GOLD’s most recent features of the month – our infographic on optimising pharma’s customer experience journey and an article on how exactly to design this experience.
Within the episode, the team explore how the industry may be missing out on insights gathered from HCPs, what makes a ‘winning’ website for HCPs and more – featuring exclusive input from Robert Tegge, Associate Principal, ZS, who shares valuable insights on what HCPs are really looking for before and after a congress.
A little more on EMJ GOLD’s guest…Robert Tegge is a leader within the ZS meetings and events practice area, which focuses on identifying insights to drive improved outcomes for our clients’ meetings programs. He collaborates with organizations to help build capabilities and solve unique problems, leveraging ZS’s technology and operations infrastructure as well as industry expertise.
Robert has a wealth of experience in strategy and operations roles across various healthcare sectors, including providers, pharmaceuticals, and medical products. In these roles, he has consistently leveraged data to provide actionable insights on a variety of sales, marketing, and growth decisions. He also holds a B.S. and an M.S. in civil engineering from the University of Illinois at Urbana-Champaign, and an MBA from Northwestern University’s Kellogg School of Management.
-
In this week’s edition of the podcast, Isabel and Jade share an interview with Dr Harmony Garges, Chief Medical Officer, ViiV Healthcare. She speaks with Dr Jonathan Sackier, Host, EMJ Podcast, who joined us in Reuters Barcelona where we meet our guest.
Together, the two discuss Harmony’s decision to join the pharmaceutical industry, how treating children with HIV needs to be approached differently, her views on improving vital access to HIV treatment and much more. This is the longer version of her Catalyst interview with us, check that out here.
-
In this week’s episode, Danie du Plessis, Executive Vice President, Pharmaceutical Operations, Kyowa Kirin, sits down with the EMJ GOLD team to share the value that patient partnerships can hold in the industry.
Danie explores how patient partnerships have evolved over the years, what companies should be doing to get them to their best potential, the value of learning from others and much more.
A little more on EMJ GOLD’s guest…After completing his medical studies and a Master’s Degree in Clinical Pharmacology in South Africa, Danie spent three years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in medical affairs, marketing and sales, pharmacovigilance and clinical operations. He has held roles such as including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. Danie joined Kyowa Kirin International in August 2019 as head of Medical Affairs and has been Executive Vice President Pharmaceutical Operations since April 2024.
He is also a Director and Chair of the Global non-profit Medical Affairs Professional Society (MAPS) Board, Fellow of the Faculty of Pharmaceutical Medicine in the UK, visiting senior lecturer at King’s College, London and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS).
-
Tune in to the latest episode of the EMJ GOLD podcast as Isabel and Jade cross the halfway point of the season with special guest host Dr Jonathan Sackier of the EMJ podcast.
In this episode, the team listen back to Jonathan's discussion with Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca at Reuters Events: Pharma 2024 in Barcelona. Together, the two unpick the current small molecule funding landscape, how to improve incentives to invest in rare diseases, how to better inform policymakers about the difference they can make and much more.
A little more on EMJ GOLD’s guest…
In Stefan’s role as SVP Europe and Canada at AstraZeneca, he is dedicated to supporting teams across 30 markets to grow the company ethically and sustainably. His focus is to improve the lives of millions of patients, with a particular emphasis on partnering to find solutions to healthcare challenges, addressing the burden of chronic disease and transforming health systems to be more future-proofed and resilient.
He’s worked at AstraZeneca for over 28 years, having joined before the merger of Astra and Zeneca in 1999, and holds a BSc and MSc in Business Administration & Economics from Stockholm University. He has additionally sat on the boards of multiple corporations, including The Swedish Chamber of Commerce and Industry in Japan, the EFPIA and most recently the Swedish Swiss Chamber of Commerce.
-
This week, Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, joins Isabel on the podcast to share how leading with love rather than ruling with an iron fist is the best way to get results in the pharmaceutical industry.
In this episode, Claire and Isabel discuss how she fell in love with science as a child, the leadership skills she has gained over the course of her career and the importance of valuing your people and being valued in return.
A little more on EMJ GOLD’s guest…Claire D'Abreu-Hayling is the Chief Scientific Officer at Sandoz, and with more than 30 years of experience in the pharmaceutical industry under her belt, she knows a thing or two about life sciences leadership - past and present. At the company Claire oversees the global product development network where she manages infrastructure strategy, pipeline execution and talent acquisition for both small molecules and biosimilars. Outside of work, Claire is a true champion of authenticity in the workplace. She is passionate about diversity, equity and inclusion and is particularly committed to mentoring Black and Asian women who are pursuing careers in STEM.
-
Join EMJ GOLD for a special edition of the podcast, in which Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education tools and skills.
In this episode, the two explore how new technological offerings, such as interactive articles, are transforming the space for medical content – enabling content creators to share research in a more impactful way and helping healthcare professionals better engage with and continue their professional development.
Check out EMJ’s interactive article mentioned in the podcast: JAK inhibitors: a new frontier in dermatology
- Visa fler
